Sun Pharma Q4 results: Profit jumps 26% to ₹2,714 crore on healthy domestic sales; ₹5/share dividend out

The NSE filings showed that Sun Pharma’s net profits surged 26% to ₹2,714 crore in the fourth quarter, compared year-on-year with ₹2,149 crore in the same period a year earlier, as per the consolidated financial statements.

The pharma company’s consolidated revenue from core operations advanced 13.6% year-on-year to ₹14,559 crore in the March quarter, from ₹12,815 crore in the same period a year ago.

Why did Sun Pharma shares fall 3% today?

Sun Pharma shares dropped 3% to their intraday low of ₹1,833.10 after the company’s Q4 earnings announcement due to the company’s poor standalone performance in the January to March period for the financial year ended 2025-26.

The company’s standalone net profits dropped 70% to ₹608 crore in the fourth quarter of the year ended 2025-26, compared with ₹2,041 crore in the same period a year ago. While the revenue from core operations dropped 31% YoY to ₹4,887 crore, from ₹7,100 crore a year ago.

Sun Pharma shares closed 2.47% lower at ₹1,844.60 after Friday’s stock market session, according to the NSE data.

Business snapshot

Sun Pharma’s formulation sales in India witnessed a 14.8% growth to ₹4,835.9 crore in the March quarter of the year ended 2025-26. According to the financial statements, the company’s domestic market sales accounted for 33.2% of the total sales in the period.

In the investor's presentation, the company disclosed its market share expanded to 8.4%, from its earlier 8.1% levels, as the pharma giant has launched 11 new products in the period under review.

However, Sun Pharma’s formulation sales in the United States dropped 1.1% to $259 million, while the innovative medicines business recorded continued momentum, which offset some of the generics business.

The company’s US sales represented for 28.8% of the total consolidated sales in the period.

“Our U.S. Innovative Medicines business has surpassed $1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company,” said Kirti Ganorkar, the MD of Sun Pharma.

Sun Pharma dividend

Sun Pharma’s board of directors also recommended a final dividend of ₹5 per share with a face value of ₹1 apiece for the financial year ended 2025-26, according to an exchange filing.

If approved in the upcoming annual meeting, Sun Pharma will pay a ₹5 per share final dividend to eligible shareholders, up to one day ahead of the pre-set record date of the corporate action.

“Final dividend of ₹5 per equity share of ₹1 each is recommended to the shareholders for their approval at the 34th Annual General Meeting (AGM) of the company,” the company informed the stock exchanges.

The company will disclose the record date of the final dividend in due time to determine the eligibility of shareholders.